Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus

Dermatologic Surgery

Volumn 34, Issue 11, 2008, Pages 1486-1499

  Carruthers, Alastair ^a,b   Carruthers, Jean ^b  

^a Carruthers Dermatology Center   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYAPATITE; MICROSPHERE; FILLER; POLYLACTIC ACID; RADIESSE; SILICON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; ERYTHEMA; FACE DISORDER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; RATING SCALE; SKIN EDEMA; TREATMENT OUTCOME; NOTE; SKINFOLD THICKNESS;

EID: 55949102895     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2008.34323.x     Document Type: Article

References (31)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998 12 : 51 8.
2. Graber A. Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection. Endo Pract 2001 7 : 430 7.
3. Koutkia P, Grinspoon S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Ann Rev Med 2004 35 : 303 17.
4. Kotler DP. XIV International AIDS Conference: Update on lipodystrophy...or is it just lipoatrophy?. Accessed on October 1, 2007.
5. Borderi M, Verucchi G, Tadolini M, et al. Metabolic complications of HIV-1-antiretroviral therapy: the lipodystrophy syndrome. New Microbiol 2001 24 : 303 15.
6. Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 2006 118 (Suppl) : 34S 45S.
7. ®) for correction of the mid- and lower face: consensus recommendations. Plast Reconstr Surg 2007 120 (Suppl) : 55S 66S.
8. Jones D. HIV facial lipoatrophy: causes and treatment options. Dermatol Surg 2005 31 : 1519 29.
9. Cofrancesco J, Brown T, Martins CR. Management options for facial lipoatrophy. AIDS Read 2004 14 : 639 40, 645-650.
10. Engelhard P. Correction options for lipoatrophy in HIV-infected patients. AIDS Patient Care STDS 2006 20 : 151 60.
11. Borelli C, Kunte C, Weisenseel P, et al. Deep subcutaneous application of poly-l-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol 2005 18 : 273 8.
12. Esch P. Caring for HIV-positive and aging patients with associated facial lipoatrophy. Plast Surg Nurs 2006 26 : 17 23.
13. ™). Dermatol Online J 2004 10 : 2.
14. Hubbard W. BioForm Implants: Biocompatibility. Franksville, WI : Bioform Inc. 2003.
15. Goldberg DJ. Calcium hydroxylapatite. In : Fillers in Cosmetic Dermatology. Abingdon, UK : Informa UK Ltd 2006. p. 81 109.
16. Marmur ES, Phelps R, Goldberg DJ. Clinical, histologic, and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther 2004 6 : 223 6.
17. ™ for facial rejuvenation. Cosmetic Dermatol 2005 18 : 823 6.
18. ®). Cosmetic Dermatol 2006 19 : 583 8.
19. Hobar PC, Pantaloni M, Byrd HS. Porous hydroxylapatite granules for alloplastic enhancement of the facial region. Clin Plast Surg 2000 27 : 557 69.
20. Smith S, Busso M, McClaren M, et al A six-month randomized, bilateral, prospective comparison of calcium hydroxylapatite microspheres in a gel carrier versus human-based collagen for the correction of nasolabial folds. Poster presented at: American Society for Dermatologic Surgery (ASDS); October 27-30, 2005 Atlanta, GA.
21. ™ FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg 2004 6 : 234 9.
22. Roth JS. Restorative treatment approaches for HIV-associated lipoatrophy. The PRS Notebook 2005 10 : 24 8.
23. Ahn MS. Calcium hydroxylapatite: Radiesse. Facial Plast Surg Clin North Am 2007 15 : 85 90.
24. James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002 28 : 979 86.
25. Sadick N. Intermediate Fillers. Chapter 6. Radiesse. In : Fillers. Cambridge Press (UK) 2007 (in press).
26. Carruthers A, Liebeskind B, Carruthers J, Forster BB. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds. Dermatol Surg 2008 34 Suppl 1 : S78 84.
27. Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg 2006 : 1336 45.
28. Leonard AL, Hanke CW. A protocol for facial volume restoration with poly-l-lactic acid. J Drugs Dermatol 2006 : 872 7.
29. Jones DH, Carruthers A, Orentreich D, et al. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy. Dermatol Surg 2004 30 : 1279 86.
30. Lowe NJ, Grover R. Injectable hyaluronic acid implant for malar and mental enhancement. Dermatol Surg 2006 32 : 881 5.
31. Gooderham M, Solish N. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol Surg 2005 31 : 104 8.